Phase II Single-Arm Trial of Cladribine and Low-Dose Cytarabine Alternating with Decitabine as Frontline Therapy for Older Patients with Acute Myeloid Leukemia

BACKGROUND: Frontline therapy for older and/or unfit patients with acute myeloid leukemia (AML) remains unsatisfactory. We studied a new lower-intensity regimen of cladribine combined with low-dose cytarabine (LDAC) alternating with decitabine (DAC) aimed to improve outcomes in this population Based...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Lancet Haematol
Auteurs principaux: Kadia, Tapan M., Cortes, Jorge, Ravandi, Farhad, Jabbour, Elias, Konopleva, Marina, Benton, Christopher B., Burger, Jan, Borthakur, Gautam, DiNardo, Courtney D., Pemmaraju, Naveen, Daver, Naval, Ferrajoli, Alessandra, Wang, Xuemei, Patel, Keyur, Jorgensen, Jeffrey L., Wang, Sa, O’Brien, Susan, Pierce, Sherry, Tuttle, Carla, Estrov, Zeev, Verstovsek, Srdan, Garcia-Manero, Guillermo, Kantarjian, Hagop
Format: Artigo
Langue:Inglês
Publié: 2018
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6775639/
https://ncbi.nlm.nih.gov/pubmed/30115541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(18)30132-7
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires